[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Indexing Sources::
Editorial Board::
Executive Members::
Articles Archive::
Instruction to Authors::
Contact Us::
Site Facilities::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Volume 22, Issue 2 (6-2020) ::
J Gorgan Univ Med Sci 2020, 22(2): 75-81 Back to browse issues page
Prevalence of Human Immunodeficiency Virus (HIV) coinfections among male prisoners in Alborz province
Shohreh Azimi1 , Azar Sabokbar2 , Amir Bairami3 , Mohammad Javad Gharavi * 4
1- Ph.D Candidate in Microbiology, Department of Microbilogy, Karaj Branch, Islamic Azad University, Karaj, Iran
2- Assistant Professor, Department of Microbilogy, Karaj Branch, Islamic Azad University, Karaj, Iran
3- Associate Professor, Department of Medical Parasitology and Mycology, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran
4- Professor, Department of Medical Parasitology and Mycology, Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran. Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran , mjgharavi@gmail.com
Abstract:   (8589 Views)
Background and Objective: Prisoners are among the high risk population for contagious infections such as HIV (Human Immunodeficiency Virus), HBV (Hepatitis B Virus), HCV (Hepatitis C Virus), TB (Tuberculosis), and other dangerous diseases. In spite of other countries in the world, data about the prevalence and risk factors for infectious diseases among prisoners are spars in Iran. The aim of this study was to determine the prevalence of HBV, HCV and TB coinfections among male prisoners suffering from HIV.
Methods: In this descriptive-analytical study, 100 HIV patients were selected. Microscopic examination (acid fast staining) was applied on sputum specimens and serological (HBsAg, anti- HCV) and molecular (Real time PCR and DNA sequencing) investigations carried out on patient’s sera.
Results: Among 100 prisoners affected with HIV, the prevalence of HCV, HBV and TB infections were 45%, 3%, and 9%, respectively. All HBV positive cases were genotype D, subgenotype ayw2. Among the HCV positive subjects, 34 (75.5%) and 11 (24.5%) were genotype 1a and genotype 3a, respectively. There was no significant relation between age, CD4 and transmission route of HCV in male prisoners affected with HIV. Drug injection was the main route for the acquisition of HCV, HBV infections.
Conclusion: This study showed that a high prevalence of HCV and TB infections among male prisoners affected with HIV.
Keywords: Human Immunodeficiency Virus [MeSH], Coinfection [MeSH], Hepatitis B Virus [MeSH], Hepatitis C Virus [MeSH], Tuberculosis [MeSH]
Article ID: Vol22-25
Full-Text [PDF 214 kb]   (10489 Downloads)    
Type of Study: Original Articles | Subject: Infectious Medicine
1. Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. Arch Iranian Med. 2003; 6(1): 1-4.
2. Thomas DL. Growing importance of liver disease in HIV-infected persons. Hepatology. 2006 Feb; 43(2 Suppl 1): S221-29. DOI: 10.1002/hep.21033
3. Park JS, Saraf N, Dieterich DT. HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep. 2006 Feb; 8(1): 67-74. DOI: 10.1007/s11894-006-0066-9
4. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006; 44(1 Suppl): S6-9. DOI: 10.1016/j.jhep.2005.11.004
5. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT; HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat. 2010 Dec; 17(12): 879-86. DOI: 10.1111/j.1365-2893.2009.01249.x
6. World Health Organization. Global hepatitis report 2017. WHO, Geneva. 2017 April.
7. Martín-Carbonero L, Poveda E. Hepatitis B virus and HIV infection. Semin Liver Dis. 2012 May; 32(2): 114-19. DOI: 10.1055/s-0032-1316466
8. Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis. 2005 Apr; 191(7): 1169-79. DOI: 10.1086/428502
9. Gupta P. Hepatitis C virus and HIV type 1 co-infection. Infect Dis Rep. 2013 Jun; 5(Suppl 1): e7. DOI: 10.4081/idr.2013.s1.e7
10. Alexiev I, Alexandrova M, Golkocheva-Markova E, Teoharov P, Gancheva A, Kostadinova A, et al. High Rate of Hepatitis B and C Coinfections Among People Living with HIV-1 in Bulgaria: 2010-2014. AIDS Res Hum Retroviruses. 2017 Mar; 33(3): 228-29. DOI: 10.1089/AID.2016.0148
11. Ziaee M, Sharifzadeh G, Namaee MH, Fereidouni M. Prevalence of HIV and hepatitis B, C, D infections and their associated risk factors among prisoners in Southern Khorasan Province, Iran. Iran J Public Health. 2014 Feb; 43(2): 229-34.
12. Rabirad N, Mohammad Nejad E, Hadizadeh MR, Begjan J, Ehsani SR. The prevalence of TB in HIV patients and risk factor with frequent referral (Iran, 2009-10). Iran Red Crescent Med J. 2013 Jan; 15(1): 58–61. DOI: 10.5812/ircmj.4401
13. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV coinfection prevalence in Iran-a systematic review and meta-analysis. J PloS one. 2016; 11(3): e0151946. DOI: 10.1371/journal.pone.0151946
14. Mohammad Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan-Iran. World J Gastroenterol. 2005 Jul; 11(26): 4085–89. DOI: 10.3748/wjg.v11.i26.4085
15. Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, Jafari Shakib A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J. 2007 Mar-Apr; 13(2): 250-56.
16. Zakizad M, Salmeh F, Yaghoobi T, Yaghoubian M, Nesami MB, Esmaeeli Z, et al. Seroprevalence of hepatitis C infection and associated risk factors among addicted prisoners in Sari-Iran. Pak J Biol Sci. 2009 Jul; 12(14): 1012-18. DOI: 10.3923/pjbs.2009.1012.1018
17. Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis. 2009 Oct; 13(5): 356-58. DOI: 10.1590/S1413-86702009000500008
18. Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci Rep. 2018 Jan; 8(1): 150. DOI: 10.1038/s41598-017-18296-9
19. Farhoudi B, SeyedAlinaghi S, Mohraz M, Hosseini M, Farnia M. Tuberculosis, hepatitis C and hepatitis B co-infections in patients with HIV in the Great Tehran Prison, Iran. Asian Pacific Journal of Tropical Disease. 2016 Jan; 6(1): 82-83. https://doi.org/10.1016/S2222-1808(15)60989-6
20. Ye S, Pang L, Wang X, Liu Z. Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia. Curr HIV/AIDS Rep. 2014 Jun; 11(2): 128-33. DOI: 10.1007/s11904-014-0206-z
21. Alavi SM, Talebi Z, Bakhtiarinia P. [Pulmonary Tuberculosis risk factors in hospitalized HIV positive patients in Ahvaz, Iran (2001-09)]. J Gorgan Uni Med Sci. 2012; 14(3): 82-86. [Article in Persian]
22. Norouzi M, Ramezani F, Khedive A, Karimzadeh H, Alavian SM, Malekzadeh R, et al. Hepatitis B Virus Genotype D is the Only Genotype Circulating in Iranian Chronic Carriers, the Unique Pattern of Genotypic Homogeneity. J Gastroenterol Hepatol Res. 2014; 3(9): 1238-43.
23. Hajia M, Amirzargar AA, Khedmat H, Shahrokhi N, Farzanehkhah M, Ghorishi SM, et al. Genotyping Pattern among Iranian HCV Positive Patients. Iran J Public Health. 2010; 39(2): 39-44.
24. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2009 Jul-Aug; 14(4): 249-58.
25. Slavuckij A, Sizaire V, Lobera L, Matthys F, Kimerling ME. Decentralization of the DOTS programme within a Russian penitentiary system. How to ensure the continuity of tuberculosis treatment in pre-trial detention centres. Eur J Public Health. 2002 Jun; 12(2): 94-98. DOI: 10.1093/eurpub/12.2.94
26. Lobato MN, Leary LS, Simone PM. Treatment for latent TB in correctional facilities: a challenge for TB elimination. Am J Prev Med. 2003 Apr; 24(3): 249-53. DOI: 10.1016/s0749-3797(02)00583-4
27. Coninx R, Maher D, Reyes H, Grzemska M. Tuberculosis in prisons in countries with high prevalence. BMJ. 2000 Feb; 320(7232): 440-42. DOI: 10.1136/bmj.320.7232.440
28. Tavakoli A. Incidence and Prevalence of Tuberculosis in Iran and Neighboring Countries, Zahedan J Res Med Sci. 2017; 19(7): e9238. DOI: 10.5812/zjrms.9238.
29. Dianatinasab M, Joulaei H, Ghorbani M, Zarei N, Rezaeian S, Fararouei M, et al. Prevalence of Tuberculosis in HIV-positive Prisoners: A Systematic Review and Meta-analysis. AIDS Rev. 2018 Apr-Jun; 20(2): 114-24. DOI: 10.24875/AIDSRev.M18000023
Send email to the article author

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Azimi S, Sabokbar A, Bairami A, Gharavi M J. Prevalence of Human Immunodeficiency Virus (HIV) coinfections among male prisoners in Alborz province. J Gorgan Univ Med Sci 2020; 22 (2) :75-81
URL: http://goums.ac.ir/journal/article-1-3554-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 2 (6-2020) Back to browse issues page
مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.05 seconds with 36 queries by YEKTAWEB 4657